Bayer’s blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case made it onto China’s 50 Representative IP cases in 2022, this time in a final judgement from the Supreme Court of an infringement case against a generic company who was marketing the patented drug before the patent expiration date. At the heart of the case is a dispute over (1) what acts by a generic…
China, China Patent Office, CNIPA, Court Cases, Courts, Invalidation, Inventions, Patent Law, Pharma, Top 10 IP Case
